Selective serotonin reuptake inhibitor fluoxetine, reduces solid tumor burden and metastasis through activation of host antitumor immune response and modulation of tumor microenvironment

Key Points

• Fluoxetine significantly reduces tumor burden and metastasis, indicating its potential as an antitumor agent.
• In preclinical models, tumor size decreased by up to 40%, showing notable effects on growth suppression.
• Assessment of immune cell activation demonstrated a marked increase in antitumor immune responses.
• These findings suggest fluoxetine may offer new therapeutic strategies for treating solid tumors, pending further research.